In particular, taking into account the results that have been reported in KEYNOTE 024 and 042 clinical trials, the adoption of pembrolizumab should be considered as the first line or as a valid second line treatment in advanced stage NSCLC patients harboring a PD-L1 expression level ≥50% or between 1–49%, respectively [20,21]. Here, CD274 is linked to non-small cell lung carcinoma.